Cell and Gene Therapy Manufacturing India: Nucelion Deal
Cell and gene therapy manufacturing India: what the Nucelion and VeGen Bio CRDMO deal covers, and what it leaves out, from marketing to the 2028 target.
Cell and Gene Therapy Manufacturing India: Nucelion Deal
Cell and gene therapy manufacturing India: what the Nucelion and VeGen Bio CRDMO deal covers, and what it leaves out, from marketing to the 2028 target.
AI Medical Search Engine Race Heats Up on $15B Report
AI medical search engine OpenEvidence is reportedly valued at $15B. How its free, ad-supported model works and what to ask about the numbers.
MMR Vaccination Push as Pennsylvania Measles Hits 1,317
MMR vaccination is rising as Pennsylvania measles reaches 1,317 cases: over 56,000 provider doses in September and 10,000 by state nurses.
Competitive Generic Therapy Exclusivity: Zydus Patch Win
Competitive Generic Therapy exclusivity may give Zydus 180 days on its new menopause patch. What the rule says, and what is still unknown.
Hospital EBITDA Impact: India’s Cancer Drug Margin Cap
Hospital EBITDA impact of India’s 30% cancer drug margin cap: the estimate, assumptions to question and key dates, 27 October and 9 November.
Indian Hospital IPOs: Paras Health Issue in Context
Indian hospital IPOs: Paras Health’s ₹1,450 crore issue, debt-repayment plan, anchor round and expansion, with risks and open questions.
OpenAI Life Sciences AI: Orchestra Bio Deal and Rosalind
OpenAI life sciences AI adds Orchestra Bio’s R&D coordination team. What Rosalind covers, what was not disclosed and what to watch.
Ebola Outbreak Africa: Nigeria Becomes Fifth Country
Ebola outbreak Africa update: Nigeria confirms an imported case in Abuja, the fifth country affected. What WHO says and what is still unknown.
Bepirovirsen FDA Approval: GSK, Ionis and the Market
Bepirovirsen FDA approval gives GSK a first-in-class hepatitis B drug. See the designations, Ionis royalties, companion test and what is undisclosed.
